Commentary

摘要

There were many important presentations on lymphoma at the 2011 American Society of Hematology (ASH) meeting. Clinical trials provided new data on agents such as brentuximab vedotin, obinu-tuzumab, and romidepsin, as well as on the use of radioimmunotherapy with cyclophosphamide, doxorubicin, vincristine, and prednisone (CHOP). Several clinical studies examined the use of brentuximab vedotin (Adcetris). I presented results from a phase I trial of brentuximab vedotin with doxorubicin, bleomycin, vinblastine, and dacarbazine (ABVD) or doxorubicin, vinblastine, and dacarbazine (AVD) in patients with newly diagnosed advanced-stage Hodg-kin lymphoma, which was built on the pivotal phase II study by Chen and colleagues that led to the drugs approval. In the previous study, brentuximab vedotin was shown to have single-agent activity in heavily pretreated patients who had relapsed after autologous transplant. The overall response rate was approximately 75%, and the complete response (CR) rate was approximately 34%.